Bruce A. Feinberg, DO

Bruce A. Feinberg, DO; Ryan Haumschild, PharmD, MS, MBA; Thomas Ollis, MS, RPh; and Joseph Mikhael, MD, discuss the future treatment landscape for the management of multiple myeloma.

Multiple myeloma experts comment on clinician education of novel therapies in the pipeline for multiple myeloma and discuss optimal routes of administration for currently available drugs.

Joseph Mikhael, MD, and Ryan Haumschild, PharmD, MS, MBA, discuss current and emerging trends in multiple myeloma treatment.

Thomas Ollis, MS, RPh, discusses the role of pharmacists and specialty pharmacy in the management of multiple myeloma.

A panel of experts in multiple myeloma review the use of quadruplet therapy in clinical practice and the impact on patients’ depth of response.

Joseph Mikhael, MD, reviews the phase 2 GRIFFIN trial evaluating the use of quadruplet therapy, daratumumab plus VRd, in patients with multiple myeloma, and the panel comments on the use of quadruplet therapy.

Multiple myeloma experts share insights on guiding treatment decisions to provide optimal care for patients.

Joe Mikhael, MD, provides an overview of minimal residual disease and assesses the prognostic impact for a patient with multiple myeloma.

Ryan Haumschild, PharmD, MS, MBA, comments on the use of triplet regimens as the standard of care treatment for patients with multiple myeloma, and Thomas Ollis, MS, RPh, shares a community practice perspective.

Joseph Mikhael, MD, reviews the history of multiple myeloma treatment and comments on the evolution of care.

This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.

Gamification in healthcare is gaining momentum, with attempts to apply gaming principles to improve patient clinical outcomes. This trend establishes the need for a “digital practitioner” who channels these games, monitors progress, and selects the most appropriate ones for a given patient.

An update on immunotherapies and the potential impact of chimeric antigen receptor (CAR)-T cells on oncology care.

Bruce A. Feinberg, DO, of Cardinal Health Specialty Solutions, published results in Evidence-Based Oncology1 showing that Cardinal's deployment of pathways had achieved measurable savings across a diverse set of healthcare providers, with an actuary's validation.

Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, Clinical Pathways, begins this next segment from a different perspective.

A statewide collaboration between payers and providers to create a cancer clinical care pathways program is successful.